; (2) the total number of agreements entered into under section 2 during such year; (3) the total amount of each covered pediatric cancer drug purchased by the Secretary pursuant to such agreements during such year; (4) the total amount of each covered pediatric cancer drug distributed from the reserve supplies under section 4 during such year; and (5) any other information that the Secretary determines relevant. 6. Definitions In this Act: (1) Covered pediatric cancer drug The term covered pediatric cancer drug means a drug— (A) that is included on the essential pediatric cancer drug list established under section 3; (B) that may be at risk of a meaningful disruption (as defined in section 506J(j) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356j(j) )) in the supply of the drug; and (C) whose final dosage form is manufactured at an eligible source facility. (2) Drug The term drug — (A) means a drug (as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321(g) )); and (B) includes a biological product (as defined in section 351(i) of the Public Health Service Act ( 42 U.S.C. 262(i) )). (3) Eligible source facility The term eligible source facility means a facility— (A) registered under section 510 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360 ); (B) lawfully manufacturing a covered pediatric cancer drug; and (C) located in— (i) the United States; or (ii) a country that is a member of the Organisation for Economic Co-operation and Development. (4) Essential pediatric cancer drug list The term essential pediatric cancer drug list means the list under section 3(a). (5) Secretary The term Secretary means the Secretary of Health and Human Services. (6) United States The term United States means each of the several States and the territories and possessions of the United States. 7. Authorization of appropriations To carry out this Act, there are authorized to be appropriated $500,000,000 for fiscal year 2024, to remain available until expended.